Guanfacine extended-release

🧮 Dose calculator

Attention-deficit/hyperactivity disorder · Regimen source: FDA Guanfacine ER · 2.2

• • Increase by no more than 1 mg/week; target 0.05–0.12 mg/kg/day (1–7 mg). Swallow whole; not with high-fat meals. Do not stop abruptly. Not interchangeable mg-for-mg with immediate-release guanfacine. FDA Guanfacine ER · 2.2FDA Guanfacine ER · 2.1FDA Guanfacine ER · 2.3

Enter age (weight is optional for this regimen).

👥 Special populations

• 🤰 PregnancyUse with caution

  Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Guanfacine ER · 8.1

  “Risk Summary Available data with guanfacine over decades of use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.”

• 🤱 BreastfeedingUse with caution

  Label: use with caution while breastfeeding; see the label text. FDA Guanfacine ER · 8.2

  “Risk Summary There are no data on the presence of guanfacine in human milk or the effects on the breastfed infant.”

• 👶 ChildrenUse with caution

  The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Guanfacine ER · 8.4

  “Safety and efficacy of guanfacine extended-release tabletsin pediatric patients less than 6 years of age have not been established.”

• 👴 Older adultsUse with caution

  Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Guanfacine ER · 8.5

  “The safety and efficacy of guanfacine extended-release tablets in geriatric patients have not been established.”

• ⚥ Females & males of reproductive potentialNo data

  The source for this drug has no section for this group.